BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics.
- In Jan 2021, Tislelizumab received approval in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer (NSCLC).
- In Late 2019, Tislelizumab (anti-PD-1 antibody) received approval from the China National Medical Products Administration (NMPA) for relapsed or treatment-resistant Hodgkin lymphoma in patients who have undergone two previous lines of therapy and is also approved for metastatic urothelial carcinoma.
- In Nov 2019, US FDA approved Zanubrutinib, sold under the brand name Brukinsa, for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy.
Page 1 of 2
